• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Ch. Acct. & Ch. Admin. Officer Mcneil Michael D. covered exercise/tax liability with 2,324 shares, decreasing direct ownership by 8% to 28,587 units (SEC Form 4)

    8/19/25 5:17:20 PM ET
    $SMTI
    Industrial Specialties
    Health Care
    Get the next $SMTI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    McNeil Michael D.

    (Last) (First) (Middle)
    1200 SUMMIT AVE
    SUITE 414

    (Street)
    FORT WORTH TX 76102

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Sanara MedTech Inc. [ SMTI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Ch. Acct. & Ch. Admin. Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    08/19/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 08/19/2025 F 2,324(1) D $30.86(1) 28,587 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents shares of common stock of Sanara MedTech Inc. (the "Issuer") withheld by the Issuer to satisfy tax withholding obligations in connection with the accelerated vesting of 9,543 shares of restricted stock previously granted to the reporting person. No shares were issued or sold in this transaction. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market.
    /s/ Michael D. McNeil 08/19/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SMTI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SMTI

    DatePrice TargetRatingAnalyst
    3/26/2025$50.00 → $51.00Buy
    H.C. Wainwright
    12/23/2024$50.00Buy
    H.C. Wainwright
    5/20/2022$45.00 → $40.00Overweight
    Cantor Fitzgerald
    6/30/2021$45.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SMTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright reiterated coverage on Sanara MedTech with a new price target

    H.C. Wainwright reiterated coverage of Sanara MedTech with a rating of Buy and set a new price target of $51.00 from $50.00 previously

    3/26/25 7:42:25 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    H.C. Wainwright initiated coverage on Smtek with a new price target

    H.C. Wainwright initiated coverage of Smtek with a rating of Buy and set a new price target of $50.00

    12/23/24 7:26:26 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    Cantor Fitzgerald resumed coverage on Smtek with a new price target

    Cantor Fitzgerald resumed coverage of Smtek with a rating of Overweight and set a new price target of $40.00 from $45.00 previously

    5/20/22 9:07:28 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    $SMTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Ch. Acct. & Ch. Admin. Officer Mcneil Michael D. covered exercise/tax liability with 2,324 shares, decreasing direct ownership by 8% to 28,587 units (SEC Form 4)

    4 - Sanara MedTech Inc. (0000714256) (Issuer)

    8/19/25 5:17:20 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    Director Tanzberger Eric D was granted 3,590 shares, increasing direct ownership by 26% to 17,658 units (SEC Form 4)

    4 - Sanara MedTech Inc. (0000714256) (Issuer)

    5/28/25 4:35:44 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    Director Salamone Ann Beal was granted 2,809 shares, increasing direct ownership by 14% to 22,704 units (SEC Form 4)

    4 - Sanara MedTech Inc. (0000714256) (Issuer)

    5/27/25 6:10:44 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    $SMTI
    SEC Filings

    View All

    SEC Form 10-Q filed by Sanara MedTech Inc.

    10-Q - Sanara MedTech Inc. (0000714256) (Filer)

    8/13/25 9:15:50 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Sanara MedTech Inc. (0000714256) (Filer)

    8/13/25 7:05:13 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Sanara MedTech Inc. (0000714256) (Filer)

    5/28/25 8:15:32 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    $SMTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited)

    Net Revenue Increased 28% Year-Over-Year in Q2; Increased 27% Year-Over-Year in First Six Months of 2025 Announces Process to Evaluate Strategic Alternatives for its Tissue Health Plus, LLC Subsidiary FORT WORTH, TX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today reported its financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Summary  ●Net revenue increased 28% to

    8/13/25 7:00:00 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech to Report Second Quarter 2025 Financial Results on August 13, 2025

    FORT WORTH, TX, July 15, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," or the "Company") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced it will report its second quarter 2025 financial results on Wednesday, August 13, 2025 before the U.S. financial markets open. The Company will host a conference call and webcast on August 13, 2025 at 8:00 a.m. Eastern Time to discuss the results of the quarter ended June 30, 2025 and hold a question and answer session at the end of the call. The toll-f

    7/15/25 4:05:00 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech Inc. Announces Launch of Tissue Health Plus Wound Care Provider Pilot Program

    Pilot program designed to provide real-world evidence in the use of Tissue Health Plus' technology platform FORT WORTH, TX, July 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced the recent launch, through its subsidiary, Tissue Health Plus, LLC ("THP"), of its wound care provider pilot program, a first of its kind, value-based wound care offering designed for payers and risk-bearing entities, as well as

    7/14/25 4:05:00 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    $SMTI
    Financials

    Live finance-specific insights

    View All

    Sanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited)

    Net Revenue Increased 28% Year-Over-Year in Q2; Increased 27% Year-Over-Year in First Six Months of 2025 Announces Process to Evaluate Strategic Alternatives for its Tissue Health Plus, LLC Subsidiary FORT WORTH, TX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today reported its financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Summary  ●Net revenue increased 28% to

    8/13/25 7:00:00 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech to Report Second Quarter 2025 Financial Results on August 13, 2025

    FORT WORTH, TX, July 15, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," or the "Company") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced it will report its second quarter 2025 financial results on Wednesday, August 13, 2025 before the U.S. financial markets open. The Company will host a conference call and webcast on August 13, 2025 at 8:00 a.m. Eastern Time to discuss the results of the quarter ended June 30, 2025 and hold a question and answer session at the end of the call. The toll-f

    7/15/25 4:05:00 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)

    Q1 Net Revenue Increased 26% Year-Over-Year FORT WORTH, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today reported its financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Summary  ●Net revenue increased 26% to $23.4 million, compared to $18.5 million in the first quarter of 2024.  ●Net loss of $3.5 million, compared to a net loss of $1.8 million in the first quar

    5/14/25 7:00:00 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    $SMTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Sanara MedTech Inc.

    SC 13G - Sanara MedTech Inc. (0000714256) (Subject)

    10/8/24 5:36:55 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    $SMTI
    Leadership Updates

    Live Leadership Updates

    View All

    Sanara MedTech Inc. Expands Executive Leadership Team with New Appointments

    Elizabeth Taylor Appointed Chief Financial Officer; Michael McNeil Appointed Chief Accounting Officer and Chief Administrative Officer FORT WORTH, TX, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today the expansion of the Company's executive leadership team with new appointments. Elizabeth Taylor has been appointed to the position of Chief Financia

    1/21/25 4:08:00 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech Inc. Announces the Appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer

    FORT WORTH, TX, April 05, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today the appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer. Zach Fleming, Sanara's Chief Executive Officer, stated, "Jake and Tyler are seasoned executives with a wealth of experience in the medical device and woun

    4/5/24 9:00:00 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech Inc. Announces the Appointment of Zachary B. Fleming as Chief Executive Officer

    FORT WORTH, TX, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara" or the "Company") (NASDAQ:SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that Zachary ("Zach") B. Fleming has been appointed Chief Executive Officer effective January 1, 2022. Ron Nixon, Sanara's Executive Chairman, stated, "Zach is an outstanding leader who has been a driving force behind the development and execution of our surgical wound strategy. During his time as President of the Surgical Division, he has overseen double-digit year over year revenue growth of our business and steered the division through the ch

    12/28/21 9:15:00 AM ET
    $SMTI
    Industrial Specialties
    Health Care